Eligo Bioscience, a Paris, France-based biotechnology company pioneering the development of novel genetic medicines, received a $5M grant from the French government.
The funding is part of the call for proposals “Innovations in Biotherapies and Bioproduction,” coordinated by the Health Innovation Agency under France 2030 strategy, operated on behalf of the French government by Bpifrance.
The company intends to allocate the amount to accelerate the advancement of its proprietary topical gene delivery platform.
Led by Dr. Xavier Duportet, CEO, Eligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing. Its in-situ delivery modality enables to perform in-situ genetic engineering of these commensal bacteria, turning them as localized bioreactors that can express high-potency biologics precisely where immune dysregulation occurs.
This grant followed the publication of its microbiome base-editing platform in Nature, securing multiple foundational patents covering in situ editing of the skin microbiome, and expanded the company’s Series B funding round to $35M.
FinSMEs
13/05/2025